From Avoidance to Action: Emerging Therapies for Management of Chronic Inducible Urticaria - Episode 6
Off-Label Biologics in CIndU: Real-World Lessons and Mixed Evidence
Anti-IgE therapy has served as a long-standing off-label mainstay across CIndU subtypes, while anti-IL-4 receptor data remain mixed, underscoring the need to match therapy to each patient and comorbidity.
"Off-Label Biologics in CIndU: Real-World Lessons and Mixed Evidence" features the panel weighing a decade of off-label biologic use in CIndU.
Dr. Cotter asks Dr. Trotter about published and personal experience with omalizumab in CIndU. Before the new approval, she used omalizumab frequently. Small studies suggest it is most effective in symptomatic dermographism and cold urticaria, and possibly less effective in cholinergic urticaria. Her clinical experience mirrors those findings.
Dr. Finklea notes that omalizumab has been the mainstay for about ten years, supported by substantial safety data. However, fear of anaphylaxis has limited its use in some dermatology clinics. Dr. Cotter describes success treating solar urticaria in Las Vegas, including teenagers who play soccer and teachers crossing schoolyards. He argues the boxed warning reflects a very low event rate and should not stop dermatologists from treating patients.
Dr. Finklea then shares a personal story. She has cholinergic urticaria, some dermographism, and some CSU. Her symptoms began at age 15 as angioedema while playing goalkeeper, and everyone assumed she was allergic to her gloves. Reaching the correct diagnosis took more than a decade. Antihistamines caused dry mouth and dry eye. Omalizumab never gave her complete control, but it helped her continue as an athlete. She still sees a role for omalizumab, especially in patients with comorbid asthma.
Dr. Cotter cautions against assuming one agent works across all subtypes. Turning to dupilumab, Dr. Finklea explains that evidence consists mainly of case reports with mixed results, often in patients with atopic dermatitis. Its trials in cholinergic and cold urticaria did not meet their endpoints. Still, she values it as a safe tool for some patients.
Dr. Trotter agrees that comorbidities often guide off-label choices. She notes that a drug failing its trial endpoint can still work well for an individual patient, reflecting disease heterogeneity.
In "RemIND Trial Results: BTK Inhibition Across Three CIndU Subtypes," the panel will dissect the phase 3 trial that led to the first approval in symptomatic dermographism.
